| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SOCS6 |
| Uniprot No | SOCS6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-535 aa |
| 活性数据 | MKKISLKTLRKSFNLNKSKEETDFMVVQQPSLASDFGKDDSLFGSCYGKDMASCDINGEDEKGGKNRSKSESLMGTLKRRLSAKQKSKGKAGTPSGSSADEDTFSSSSAPIVFKDVRAQRPIRSTSLRSHHYSPAPWPLRPTNSEETCIKMEVRVKALVHSSSPSPALNGVRKDFHDLQSETTCQEQANSLKSSASHNGDLHLHLDEHVPVVIGLMPQDYIQYTVPLDEGMYPLEGSRSYCLDSSSPMEVSAVPPQVGGRAFPEDESQVDQDLVVAPEIFVDQSVNGLLIGTTGVMLQSPRAGHDDVPPLSPLLPPMQNNQIQRNFSGLTGTEAHVAESMRCHLNFDPNSAPGVARVYDSVQSSGPMVVTSLTEELKKLAKQGWYWGPITRWEAEGKLANVPDGSFLVRDSSDDRYLLSLSFRSHGKTLHTRIEHSNGRFSFYEQPDVEGHTSIVDLIEHSIRDSENGAFCYSRSRLPGSATYPVRLTNPVSRFMQVRSLQYLCRFVIRQYTRIDLIQKLPLPNKMKDYLQEKHY |
| 分子量 | 65.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组人SOCS6蛋白相关的文献示例(部分参考文献信息为示例性概括，具体内容请通过学术数据库核实)：
---
1. **"Structural insights into SOCS6-Elongin B/C interaction"**
Zhang, Y. et al. (2015). *J. Biol. Chem.*
摘要：通过X射线晶体学解析了SOCS6的SH2结构域与Elongin B/C复合物的三维结构，揭示了其负调控细胞因子信号传导的分子机制。
2. **"SOCS6 suppresses tumor growth by targeting EGFR signaling in colorectal cancer"**
Haque, S. et al. (2017). *Oncogene*
摘要：发现SOCS6通过泛素化降解EGFR蛋白抑制结直肠癌细胞增殖和迁移，提出其作为肿瘤抑制因子的潜在治疗价值。
3. **"SOCS6 modulates HIV-1 replication by regulating viral protein trafficking"**
Nie, Z. et al. (2019). *PLoS Pathog.*
摘要：证明重组人SOCS6蛋白可干扰HIV-1病毒Gag蛋白的细胞内运输，抑制病毒组装和释放，提示其在抗病毒治疗中的作用。
4. **"SOCS6 as a metabolic regulator in insulin signaling pathways"**
Yang, L. et al. (2021). *Cell Rep.*
摘要：发现SOCS6负调控胰岛素受体底物(IRS)的磷酸化，影响葡萄糖代谢，为代谢综合征治疗提供新靶点。
---
**注意**：上述文献标题和摘要内容为模拟概括，真实文献需通过PubMed/Google Scholar检索确认。推荐使用关键词 **SOCS6 protein structure/function** 或 **SOCS6 signaling pathway** 获取最新研究。
Suppressors of Cytokine Signaling 6 (SOCS6) is a member of the SOCS family, a group of intracellular proteins that regulate cytokine signaling and immune responses. SOCS6. encoded by the *SOCS6* gene in humans, acts as a negative feedback inhibitor of signaling pathways, particularly those involving receptor tyrosine kinases (RTKs) and the JAK-STAT cascade. Structurally, it contains a central SH2 domain that binds phosphorylated tyrosine residues on target proteins and a C-terminal SOCS-box motif mediating interactions with ubiquitin ligase complexes, facilitating substrate degradation.
Unlike other SOCS members (e.g., SOCS1/SOCS3), SOCS6 lacks a kinase inhibitory region (KIR) but exerts its regulatory effects by promoting proteasomal degradation of specific signaling molecules or competing for receptor-binding sites. Studies suggest its involvement in insulin signaling, growth factor receptor modulation (e.g., EGFR), and T-cell receptor signaling. It is broadly expressed in tissues, with higher levels in the liver, spleen, and immune cells.
Pathologically, SOCS6 is linked to metabolic disorders, cancer, and autoimmune diseases. Downregulation of SOCS6 has been observed in hepatocellular carcinoma and diabetes, correlating with hyperactivated RTK pathways. Conversely, its overexpression can suppress cell proliferation and tumor growth. Recombinant human SOCS6 protein, often produced in *E. coli* or mammalian systems, is utilized to study protein-protein interactions, signaling mechanisms, and therapeutic targeting. Current research focuses on its potential as a biomarker or therapeutic agent for metabolic syndromes and malignancies.
×
